One in nine American adults is now taking a GLP-1, up from 3% two years ago, and Scott's thesis is that most of us will be on one within three years — not for obesity, but for inflammation, cognition, and longevity. Dr. Melanie Jay, director of NYU Langone's Comprehensive Program on Obesity Research, isn't there yet. These drugs haven't been tested in healthy people, and she says the cost-benefit math that's well established in patients with obesity simply doesn't exist for everyone else. The two of them get into why two-thirds of patients stop within a year, why real-world weight loss comes in at roughly half what the trials reported, what a properly supported protocol actually looks like, and why the unregulated peptide stacks people are bragging about keep her up at night.
If you’re not a Prof G+ subscriber yet and want access to these weekly deep dives, make sure to subscribe below for all of Prof G Media’s exclusive content, plus livestreams and ad-free pods.
